Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2014. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMR), and connected persons, in accordance with DTR 3.1.4 R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
The filing discloses the acquisition of GSK Ordinary shares on October 6, 2014, at a price of 1,440.375 pence per share. These acquisitions resulted from the re-investment of dividends on shares held within an Individual Savings Account (ISA). The specific transactions were:
- Sir Andrew Witty (Director): 108 shares
- Mr D S Redfern (Director): 20 shares
- Mrs V A Whyte (Director): 17 shares
- Lady C Witty (Connected Person): 21 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Points
- Verify the share price of 1,440.375 pence per Ordinary share on October 6, 2014.
- Confirm the total number of shares acquired by directors and connected persons via dividend re-investment.
- Review the full list of directors and PDMRs to ensure all required disclosures are complete.